Skip to content
Concord Drugs logo

Concord Drugs

538965 BSE
Price unavailable

Concord Drugs (CONCORD) share price was ₹64.01 at the 28 Oct 2026 close; market capitalisation ₹84.36 Cr; P/E (TTM) 40.26; sector Healthcare. The share price fell 7.0% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 56.2% year on year to ₹20.90 Cr and net profit was ₹1.11 Cr, against ₹0.11 Cr a year earlier (compared with Jun 2025). Promoters held 45.08% of Concord Drugs in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 41/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹64.01 −2.18 −3.29% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹84.36 Cr
P/E (TTM)
40.26
EBITDA
₹4.60 Cr
Return on Equity
2.17%
Debt to Equity
0.26
Book Value
₹35.43
EPS (TTM)
₹1.59
52W High
₹92.52
52W Low
₹59.99

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.1035.034,23,747 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,625.0087.362,55,514 Cr15.240.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,595.5072.141,74,798 Cr9.510.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,183.00107.861,17,950 Cr22.260.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,179.5026.251,17,656 Cr4.340.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,340.8034.731,11,914 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.6032.841,10,725 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
Concord Drugs (this company)
—40.2684 Cr1.810.00%2.17%5.92%86 Cr2 Cr
Median 8 companies₹1,766.1037.651,17,803 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

41 Weak
Overall score

Data confidence 100/100

Category scores

Quality Poor 32
Returns, margins, earnings quality 22% weight
Valuation Poor 28
Cheap vs sector & own history 24% weight
Growth Strong 99
Sales & profit trajectory 9% weight
Financial Health Average 49
Solvency, leverage, coverage 9% weight
Momentum Poor 22
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is expected to give good quarter

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -9.31%
  • The company has delivered a poor sales growth of 8.12% over past five years.
  • Company has a low return on equity of 1.63% over last 3 years.

Technical Indicators

Oscillators

Neutral

Bearish
2
Neutral
5
Bullish
2

Overall

Bearish

Bearish
12
Neutral
5
Bullish
2

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
73.95% higher than 3Y

change over 1 year

Net Income Growth
267% higher than 3Y

change over 1 year

Cash Flow Change
-255%

change over 1 year

EBITDA Margin Change
-36.97%

change over 1 year Operating margin 10.72% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
8.79
7.38
12.62
14.47
6.35
11.84
10.77
7.96
13.38
10.07
16.84
35.56
20.9
Expenses
7.39
5.85
12.06
14.28
5.62
11.05
9.45
7.03
12.44
9.06
15.96
34.13
18.66
Operating Profit
1.4
1.53
0.56
0.19
0.73
0.79
1.32
0.93
0.94
1.01
0.88
1.43
2.24
OPM %
15.93%
20.73%
4.44%
1.31%
11.5%
6.67%
12.26%
11.68%
7.03%
10.03%
5.23%
4.02%
10.72%
Other Income
0
0.01
0
0
0
0.01
0
0
0
0
0.02
0
0
Interest
0.39
0.39
0.43
0.38
0.37
0.39
0.43
0.53
0.42
0.4
0.3
0.34
0.35
Depreciation
0.38
0.38
0.38
0.39
0.34
0.34
0.37
0.37
0.37
0.34
0.3
0.35
0.35
PBT
0.63
0.77
-0.25
-0.58
0.02
0.07
0.52
0.03
0.15
0.27
0.3
0.74
1.54
Tax %
23.81%
31.17%
-4%
-39.66%
50%
28.57%
57.69%
33.33%
26.67%
29.63%
26.67%
28.38%
27.92%
Net Profit
0.49
0.53
-0.24
-0.35
0.01
0.05
0.22
0.01
0.11
0.19
0.22
0.52
1.11
EPS (₹)
0.53
0.57
-0.24
-0.35
0.01
0.05
0.22
0.01
0.11
0.19
0.17
0.39
0.84
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
40.02
50.68
57.43
51.8
48.08
51.34
51.33
58.96
51.31
43.26
36.93
75.85
83.37
Expenses
32.99
42.38
51.93
47.02
44.43
48
48.11
53.37
46.97
39.58
33.16
71.61
77.81
Operating Profit
7.03
8.3
5.5
4.78
3.65
3.34
3.22
5.59
4.34
3.68
3.77
4.24
5.56
OPM %
17.57%
16.38%
9.58%
9.23%
7.59%
6.51%
6.27%
9.48%
8.46%
8.51%
10.21%
5.59%
6.67%
Other Income
0.37
0.15
0.09
0.14
0.09
0.12
3.86
0.1
0.01
0.01
0.01
0.03
0.02
Interest
2.72
2.57
2.36
1.88
1.59
1.54
1.42
1.68
1.62
1.59
1.72
1.46
1.39
Depreciation
3.63
2.91
2.58
2.4
1.71
1.46
1.37
1.76
1.6
1.54
1.42
1.36
1.34
PBT
1.05
2.97
0.65
0.64
0.44
0.46
4.29
2.25
1.13
0.56
0.64
1.45
2.85
Tax %
33.33%
40.74%
73.85%
50%
9.09%
28.26%
23.54%
28.89%
21.24%
25%
54.69%
28.28%
—
Net Profit
0.7
1.75
0.16
0.32
0.41
0.33
3.28
1.59
0.89
0.42
0.3
1.04
2.04
EPS (₹)
0.97
2.42
0.22
0.41
0.52
0.38
3.75
1.82
0.96
0.42
0.3
0.79
1.59
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
7.24
7.24
7.24
7.86
7.86
8.74
8.74
8.74
9.32
10
10
13.18
Reserves
6.07
7.82
11.75
11.46
15.29
14.74
18.02
19.62
22.38
23.82
24.11
35.34
Borrowings
21.27
19.99
15.43
13.62
9.83
9.57
12.97
16.43
15.63
14.93
16.91
12.52
Other Liabilities
19.63
17.44
21.11
73.48
49.79
24.96
10.15
11.66
9.31
7.55
7.56
10.82
Total Liabilities
54.21
52.49
55.53
106
82.77
58.01
49.88
56.45
56.64
56.3
58.58
71.86
Fixed Assets
18.32
15.18
13.64
13.51
11.85
10.52
13.83
13.97
12.86
11.63
12.17
11.55
CWIP
0
0
0
0
0.29
1
0
0.55
0.92
1.63
2
2.43
Investments
0
0
0
0
0
0
0
0
1.42
1.62
1.62
1.62
Other Assets
35.89
37.31
41.89
92.91
70.63
46.49
36.05
41.93
41.44
41.42
42.79
56.26
Total Assets
54.21
52.49
55.53
106
82.77
58.01
49.88
56.45
56.64
56.3
58.58
71.86
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1.75
3.05
1.7
6.88
1.19
2.48
1.62
0.77
2.24
1.96
2.04
-6.22
Investing
-1.1
0.23
-1.04
-2.21
-0.34
-0.84
-3.67
-2.44
-2.27
-1.21
-2.32
-1.13
Financing
-0.7
-3.42
-3.94
-4.8
-0.73
-1.79
2.07
1.68
0.05
-0.69
0.26
7.51
Net Cash Flow
-0.06
-0.14
-3.28
-0.13
0.12
-0.15
0.02
0.01
0.03
0.06
-0.02
0.16
Free Cash Flow
0.65
3.28
0.66
4.6
0.85
1.63
-2.05
-1.69
1.38
0.94
-0.29
-7.39
CFO/OP
33
51
38
152
36
78
65
26
60
59
59
-137
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
250
184
99.46
501
368
181
147
142
116
118
125
135
Inventory Days
65.82
76.39
87.31
157
172
141
101
152
156
203
253
103
Days Payable
208
92.05
130
559
393
110
26.76
62.25
45.98
35.17
45.03
33.73
Cash Conversion Cycle
108
168
57.27
98.98
146
212
221
231
227
285
333
204
Working Capital Days
68.04
113
4
79.27
102
103
140
112
145
127
144
148
ROCE %
11.35%
16.06%
8.67%
7.48%
6.16%
6.06%
5.36%
9.3%
5.97%
4.48%
4.73%
5.19%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Concord Drugs insights

61 extracted metrics + investor summaries across FY12–FY27.

Shareholding Pattern

Public54.29%Others0.63%Promot.45.08%As ofSep 2026

Documents

Frequently Asked Questions about Concord Drugs

What does Concord Drugs Ltd do?
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on approved formulations
Where is Concord Drugs Ltd (CONCORD) listed?
Concord Drugs Ltd trades under code 538965 on the BSE.
Which sector does Concord Drugs Ltd belong to?
Concord Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Concord Drugs Ltd?
Concord Drugs Ltd has a market capitalisation of ₹84.36 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Concord Drugs Ltd?
Concord Drugs Ltd trades at a PE ratio of 40.26 as of 28 Oct 2026, on earnings per share of ₹1.59, against a book value of ₹35.43 per share.
What is the 52-week high and low of Concord Drugs Ltd?
Over the last 52 weeks Concord Drugs Ltd has traded between ₹59.99 and ₹92.52 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Concord Drugs Ltd?
Concord Drugs Ltd reported a return on equity of 2.17%. Its debt-to-equity ratio is 0.26.

Company Information

Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on approved formulations

Website concorddrugs.in
Listed 2015-02-23
Face Value ₹ 10
Shares Outstanding 1,31,79,572

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/538965.md for Concord Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month